Company environment · Small-molecule immunology · multi-indication labeling
Small-molecule immunology Complete Response resubmission & Type II variation
FDA Complete Response NDA resubmission and subsequent EMA Type II efficacy variation.
1What does this company do?
Originator immunology sponsor managing a JAK inhibitor across an FDA Complete Response Letter (CRL) resubmission and a subsequent EMA Type II indication variation.
2Where is the product on its way to patients?
Oral selective JAK inhibitor across US rheumatology NDA resubmission and EU dermatology Type II variation.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
Two dated filing freezes: the post-CRL NDA resubmission USPI lock and the subsequent Type II variation Module 2.7.4 safety summary.
4Tasks
2 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →